Tecnica di Aspirazione Doppia Continua con Sistema Zoom per l'Ictus (ADAPT 2 0)
Valutazione Clinica della Tecnica di Aspirazione Doppia Continua con Sistema Zoom per Ictus (ADAPT 2.0)
This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Pojai Phattanagosai
- Numero di telefono: 650-740-7703
- Email: pphattanagosai@Imperativecare.com
Backup dei contatti dello studio
- Nome: Emma Pham
- Numero di telefono: 408-421-7684
- Email: epham@imperativecare.com
Luoghi di studio
-
-
Alabama
-
Huntsville, Alabama, Stati Uniti, 35801
- Reclutamento
- Huntsville Hospital
-
Contatto:
- Farrar Hickey
-
Investigatore principale:
- R. Dana Tomalty, MD
-
-
California
-
Walnut Creek, California, Stati Uniti, 94598
- Reclutamento
- John Muir Health
-
Investigatore principale:
- Benjamin Yim, MD
-
Contatto:
- Melenie Aaron
-
-
Florida
-
Tampa, Florida, Stati Uniti, 33606
- Reclutamento
- University of South Florida
-
Investigatore principale:
- Maxim Mokin, MD
-
Contatto:
- Kilaun Robinson
-
-
Georgia
-
Marietta, Georgia, Stati Uniti, 30060
- Reclutamento
- Wellstar Kennestone Hospital
-
Contatto:
- Autumn Lee
-
Investigatore principale:
- Ahmad Khaldi, MD
-
-
Louisiana
-
Lafayette, Louisiana, Stati Uniti, 70503
- Reclutamento
- Ochsner Clinic Foundation (Lafayette)
-
Investigatore principale:
- Shail Thanki, MD
-
New Orleans, Louisiana, Stati Uniti, 70121
- Reclutamento
- Ochsner Clinic Foundation
-
Investigatore principale:
- James Milburn, MD
-
Contatto:
- Jessica Henry
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21201
- Reclutamento
- University of Maryland
-
Investigatore principale:
- Jacob Cherian, MD
-
Contatto:
- Katie Henry
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Reclutamento
- Allina Health
-
Contatto:
- Emeryth Beloy
-
Investigatore principale:
- Collin Torok, MD
-
-
New York
-
Albany, New York, Stati Uniti, 12208
- Reclutamento
- Albany Medical College
-
Investigatore principale:
- Alexandra Paul, MD
-
Contatto:
- Chelsey Large
-
Buffalo, New York, Stati Uniti, 14203
- Reclutamento
- University at Buffalo Neurosurgery
-
Investigatore principale:
- Jason Davies, MD
-
Contatto:
- Ellen Carl
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- Weill Cornell Medicine
-
Contatto:
- Hanah Hwang
-
Investigatore principale:
- Amol Mehta, MD
-
New York, New York, Stati Uniti, 10029
- Reclutamento
- Icahn School of Medicine at Mount Sinai
-
Contatto:
- Kevin Buttet
-
Investigatore principale:
- Michael T Caton, MD
-
Syracuse, New York, Stati Uniti, 13210
- Reclutamento
- SUNY Upstate Medical Center
-
Contatto:
- Saptarshi Prachi
-
Investigatore principale:
- Haydn Hoffman, MD
-
The Bronx, New York, Stati Uniti, 10467
- Reclutamento
- Montefiore Medical Center
-
Contatto:
- Genesis Liriano
-
Investigatore principale:
- Amanda Baker, MD
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45220
- Reclutamento
- TriHealth Good Samaritan Hospital
-
Investigatore principale:
- Andrew Ringer, MD
-
Contatto:
- Mehnaaz Ali
-
Columbus, Ohio, Stati Uniti, 43221
- Reclutamento
- The Ohio State University Wexner Medical Center
-
Investigatore principale:
- Patrick Youssef, MD
-
Investigatore principale:
- Shahid Nimjee, MD
-
Contatto:
- Edward Belizaire
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Reclutamento
- University of Oklahoma, Health Science Center
-
Investigatore principale:
- Hakeem Shakir, MD
-
Contatto:
- Sanaa Hameed
-
-
South Carolina
-
Greenville, South Carolina, Stati Uniti, 29605
- Reclutamento
- Prisma Health - Upstate
-
Contatto:
- Shawn Manos
-
Investigatore principale:
- Jan Vargas Machaj, MD
-
-
Tennessee
-
Knoxville, Tennessee, Stati Uniti, 37902
- Reclutamento
- Fort Sanders Regional Medical Center
-
Contatto:
- Cameron Carter
-
Investigatore principale:
- Robert Hixson, MD
-
Memphis, Tennessee, Stati Uniti, 38120
- Reclutamento
- Semmes Murphey Foundation
-
Investigatore principale:
- Lucas Elijovich, MD
-
Contatto:
- Wendell Barnett
-
-
Texas
-
Kingwood, Texas, Stati Uniti, 77339
- Reclutamento
- HCA Houston Healthcare Kingwood
-
Investigatore principale:
- Mohamad Ezzeldin, MD
-
Contatto:
- Swathi Potla
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- Methodist Healthcare System of San Antonio
-
Contatto:
- Samantha Franklin
-
Investigatore principale:
- Lee Birnbaum, MD
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- University of Texas Science Health Center at San Antonio
-
Investigatore principale:
- Justin Mascitelli, MD
-
Contatto:
- Athena Lazaris-Conner
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84112
- Reclutamento
- University of Utah
-
Contatto:
- Andrew Grandemange
-
Investigatore principale:
- Robert Rennert, MD
-
-
Virginia
-
Falls Church, Virginia, Stati Uniti, 22042
- Reclutamento
- Inova Fairfax Medical Campus
-
Contatto:
- Lauren Monroe
-
Investigatore principale:
- James McEachern, MD
-
-
Washington
-
Spokane, Washington, Stati Uniti, 99204
- Reclutamento
- Providence Sacred Heart Medical Center and Children's Hospital
-
Contatto:
- Kyle Kramer
-
Investigatore principale:
- Christopher Zylak, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Adult subjects with acute ischemic stroke secondary to large vessel occlusion (LVO) meeting the study eligibility criteria and providing written informed consent.
Descrizione
Inclusion Criteria:
- Subject is ≥ 18 years of age
- Subject or legally authorized representative has provided written informed consent prior to any study-specific procedures and no later than 72 hours after the index procedure
- Pre-stroke mRS 0-2
- Subject is undergoing or has undergone an aspiration thrombectomy using the Zoom System with Continuous Dual Aspiration Technique (CDAT) as the first line device within its intended use
Exclusion Criteria:
- Subjects with a life expectancy of less than 6 months
- Female subject who is known to be pregnant at time of admission
- Any intracranial hemorrhage in the qualifying head CT or MRI
- Presence of tandem internal carotid artery occlusion, multiple occlusion locations (e.g., cavernous ICA and M1, separate M2 occlusions, etc.), or occlusions in multiple territories (e.g., MCA and ACA, bilateral, etc.).
- In the opinion of the Investigator, the patient is not a suitable candidate for intervention with the Zoom System
- Subject is currently enrolled in or planned to be enrolled in any concurrent interventional study that may impact the safety or performance data collected in this study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
ADAPT 2.0: Zoom System with Continuous Dual Aspiration Technique (CDAT)
The Zoom System is intended to be used as the first-line device and utilized within the FDA-cleared indications for use, consistent with the approved labeling and intended anatomical targets. |
Aspiration neurothrombectomy using Zoom System with Continuous Dual Aspiration Technique (CDAT)
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of patients achieving modified Thrombolysis in Cerebral Infarction (mTICI) score of ≥2c at the end of procedure, as adjudicated by independent core-lab
Lasso di tempo: End of procedure
|
mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
End of procedure
|
|
Rate of Embolization to New Territory (ENT) on final angiography at the end of the procedure by investigator assessment
Lasso di tempo: End of procedure
|
Embolization to New Territory (ENT), defined as the presence of new occlusions on final angiography that occur in vascular territories remote from those effected by index stroke, as assessed by the investigator |
End of procedure
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time to achieve mTICI≥2c, defined as groin puncture to investigator assessment for mTICI≥2c
Lasso di tempo: Intraprocedural
|
The time from groin puncture to mTICI (modified treatment in cerebral infarction) score ≥ 2c using study device and technique. mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the Zoom POD
Lasso di tempo: Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within at least one of the Zoom PODs |
Intraprocedural
|
|
Proportion of cases with clot captured within the Zoom POD connected to the outer aspiration catheter
Lasso di tempo: Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the outer Zoom PODs |
Intraprocedural
|
|
Rate of rescue therapy
Lasso di tempo: Intraprocedural
|
Proportion of cases with rescue therapy, defined as unplanned use of another manufacturer's thrombectomy device, angioplasty, or stenting within the target vessel territory to achieve mTICI≥2c. |
Intraprocedural
|
|
Rate of functional independence (mRS 0-2) at 90 days
Lasso di tempo: 90 days post-procedure
|
Proportion of patients achieving mRS (modified Rankin Scale) ≤2 at 90 days mRS range: 0 to 6; The mRS scale ranges from 0 (no symptoms) to 5 (severe disability), with an additional category of 6 for death; higher score means worse outcome |
90 days post-procedure
|
|
Proportion of patients achieving First Pass Effect (FPE) mTICI ≥2c as adjudicated by independent core-lab
Lasso di tempo: Intraprocedural
|
Proportion of cases achieving First Pass Effect (FPE), defined as mTICI ≥2c after the first pass with the study device and technique as adjudicated by independent core-lab mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Rate of symptomatic intracranial hemorrhage (sICH), as confirmed by imaging and independently adjudicated by medical monitor, at the 24-hour post-procedure
Lasso di tempo: 24-hour post-procedure
|
Independently adjudicated rate of symptomatic intracranial hemorrhage (sICH) defined as any apparently extravascular blood in the brain or within the cranium confirmed by imaging that is associated with clinical deterioration as defined by an increase of four or more points in the NIHSS at 24 hours compared to the baseline assessment, or that led to death, and was judged to be the predominant cause of a neurologic deterioration or death, per ECASS III criteria |
24-hour post-procedure
|
|
90-day all-cause mortality
Lasso di tempo: 90 days post-procedure
|
Rate of all-cause mortality through 90 days post-procedure |
90 days post-procedure
|
|
Rate of device-related Serious Adverse Events, independently adjudicated medical monitor
Lasso di tempo: Intraprocedural
|
Independently adjudicated rate of Serious Adverse Events related to study device |
Intraprocedural
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: David Fiorella, MD, Stony Brook University
- Investigatore principale: Shahram Majidi, MD, Icahn School of Medicine at Mount Sinai
- Investigatore principale: Justin Masciteli, MD, The University of Texas Health Science Center at San Antonio
- Investigatore principale: Maxim Mokin, MD, University of South Florida
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- ICI-2025-003
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .